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Abstract 
  
Propafenone is a class 1C antiarrhythmic drug used for the treatment of 
ventricular arrhythmias. Propafenone is a chiral compound which is normally 
administered as the racemate. The use of racemate therapy can be 
problematic as variability in both the pharmacodynamic and pharmacokinetic 
properties of the separate enantiomeric forms of the drug can exist. 
Propafenone enantiomers have been shown to have similar pharmacological 
properties, but studies are limited with regards to their disposition and 
interaction with drug metabolising enzymes. The aim of the study conducted 
here was to investigate the interaction of racaemic propafenone with the 
major cytochrome P450 isoforms (CYP2D6, CYP1A2, CYP3A4 and 
CYP2C19) to determine any stereospecific differences which may exist. This 
was conducted by measuring the in vitro metabolism of propafenone 
(racemate and enatiomers) and by developing CYP inhibition screens which 
could prove to be useful in providing information of potential drug interactions. 
In addition, stereospecific binding to human albumin was measured to 
investigate whether any enantiomeric differences in unbound drug exist. 
For the inhibition studies propafenone (racemate and enatiomers) was 
incubated in 96 well plates with separate CYP isoforms in the presence of a 
NADPH regenerating system. CYP activity was monitored using the following 
fluorogenic substrates: CYP2C19/ CYP1A2 – CEC; CYP2D6 – AMMC; 
CYP3A4 - BFC. IC50 values were calculated and compared to those of control 
inhibitors (CYP2C19 – Tranycylpromine; CYP2D6 – Quinidine; CYP3A4 – 
Ketoconazole ; CYP1A2 - Furafylline). In vitro metabolism was conducted 
using human liver microsomes incubated with propafenone (racemate and 
enatiomers) and the degree of metabolism measured using hplc analysis. 
Protein binding was estimated for propafenone (racemate and enatiomers) by 
a chromatographic method utilising a chiral HSA column.  
Inhibition studies showed that the lowest IC50 values were obtained when 
propafenone was co-incubated with CYP2D6 and CYP 3A4 which is to be 
expected as these CYP isoforms have been shown previously to be the major 
ones responsible for phase 1 metabolism of racaemic propafenone. There 
was a distinct stereospecific difference with these isoforms, with the R-
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enantiomer showing a higher degree of inhibition. This would suggest that 
there may be merit in considering single enantiomer therapy (in this instance 
using the S-enantiomer) to minimise the risk of any drug-drug interactions in 
vivo. However, the in vitro metabolism study showed that both single 
enantiomers were metabolised at a higher rate than the racaemic mixture. 
This may be explained in terms of the 2 enantiomers competing for 
metabolism and thus inhibiting the metabolism of each other. These results 
suggest a possible problem with single enantiomer therapy of propafenone as 
this drug has a short half life and increased metabolism would decrease this 
even further. Investigations into the plasma protein binding of propafenone 
showed that there is no difference in the binding of the separate enantiomers 
and therefore there would be no stereospecific differences in free drug 
concentration, although propafenone also binds to acid glycoprotein and so 
binding studies with separate enantiomers need to be conducted with this 
protein too. 
Overall, this study shows how in vitro techniques can be utilised to investigate 
stereospecific differences in drug disposition. The work described here 
warrants further study on the metabolism/disposition of propafenone 
enantiomers in vivo to examine the clinical implications of enantiospecific 
therapy with this drug. 
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1.0 Introduction 
1.1 Aim of the study 
Propafenone is a class IC antiarrhythmic drug used for the treatment of 
ventricular arrhythmias. The drug contains a chiral centre and so exists in two 
separate enantiomeric forms although it is normally administered as the 
racemate (Zhong and Chen, 1999). Indeed, propafenone is one of a number 
of such compounds which are administered as racemates. Other 
antiarrhythmic drugs also administered as racemates include encainide, 
flecainide and verapamil (Hanada et al, 2008). 
The aim of this study is to determine any stereospecific differences in the 
metabolism and distribution of the enantiomers of propafenone and to 
consider how this could affect the therapeutic efficacy of propafenone. 
 
1.2 Cardiovascular disorders and drug therapy 
It has been reported that diseases of the heart and circulatory system are the 
main course of death in Europe; accounting for 4.3 million deaths each year 
(British Heart Foundation, 2008). Throughout the world we invest millions of 
pounds in research and preventative therapies and treatments for diseases of 
the heart e.g. in 2008 alone £8.4 million was given to Oxford University to aid 
this research. As cardiovascular disease is Britain’s biggest killer it is vital that 
research is carried out to ultimately reduce the mortality rate of heart disease. 
 Certain pathophysiological disorders can lead to conditions such as 
tachycardia and atrial fibrillation whereby antiarrhythmic dugs may be 
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prescribed.  It is important to know as much about these drugs as they have 
such a narrow therapeutic index which is an indication of the toxicity of a 
compound (see section 1.4). The therapeutic index compares the 
concentration of a drug required to be effective with that which is toxic; the 
lower this number, the smaller the therapeutic window i.e. the smaller the 
difference between an effective and toxic drug concentration (Poschel et al, 
1985; Klotz, 2007). Antiarrhythmic drugs are subdivided according to the 
classification in Table 1.1. Class I drugs (including propafenone) are primarily 
sodium channel blockers which prevent sodium from entering the cell and 
therefore delay depolarization and contraction of the heart (Fuster et al, 
2001). Class II consist of beta blockers, class III contain potassium channel 
blockers which delay potassium from leaving the cell and repolarization from 
occurring and class IV consist of calcium channel blockers (Gard, 2001). 
Table 1.1 The 4 classes of antiarrhythmic drugs and examples of each 
(www.CVpharmaology.com) 
Class I Class II Class III Class IV 
Quinidine Propranolol Amiodarone Verapamil 
Lidocaine Nadolol Ibutilide Diltiazem 
Flecainide penbutolol dronedarone Nitrendipine 
 
1.2.1 Propafenone Pharmacology. 
Propafenone binds to and blocks the fast sodium channels which are 
responsible for the rapid depolarization of myocardial cells (and hence is 
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classed as a type IC antiarrhythmic agent). As with other drugs in this class 
e.g. flecainide and encainide, the dissociation of propafenone from the sodium 
channel is slow. In a normal heart the contraction is triggered by the 
depolarization of the myocardial cells originating from the sinoatrial node 
(phase 0) (Fig 1.1), when this occurs it allows the sodium channels to open 
and sodium to enter the cell and the increased permeability to sodium causes 
a sharp rise of phase 0 (Keynes, 2001). Phase 1 indicates the closure of the 
sodium channels, phase 2 indicates a plateau which is caused by calcium 
ions moving into the cell and the movement of potassium ions out to allow the 
cell to repolarize which is phase 3. Between the period of phase 0 and 3 the 
cell is in a refractory period where it cannot undergo stimulation (Sparks, 
1987). The initial depolarization occurs when the electrical current is 
transferred to neighbouring cells which in turn become depolarized which 
causes the atria to contract; this is known as the P wave. When the P wave 
reaches the atrio-ventricular node the impulse is passed to the bundle of HIS 
and the purkinje fibres which results in depolarization of the ventricles which 
contract 
(Garratt and Statter, 2001). When the sodium channels are blocked the slope 
of phase 0 decreases as a result and the amplitude of the action potential 
similarly decreases. The effect of reducing the rate and amplitude of 
depolarization by the blockage of sodium channels facilitates the reduced 
conduction velocity in non-nodal tissue. This causes the transmission of 
action potentials across the heart to reduce, which suppresses the irregular 
conduction that can lead to tachycardia therefore the conduction of electrical 
signals across the heart is slowed and the heart is less excitable 
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Figure 1.1. The cardiac action potential showing the different phases of 
depolarisation and repolarisation. (Sparks, 1987) 
 
Propafenone also displays beta adrenoreceptor blocking activity (Zehender et 
al, 1992). Beta blockers inhibit normal sympathetic effects that act through 
these receptors which would increase heart rate. In addition, some beta 
blockers, when they bind to beta-adrenoceptors, they partially activate the 
receptor while preventing norepinephrine from binding to the receptor. This 
action provides a background of sympathetic activity whilst preventing the 
normal or heightened activity that would normally occur. Therefore, beta-
blockers ultimately cause a decrease in heart rate, contractility, conduction 
velocity, and relaxation rate. Beta-blockers also possess what is referred to as 
membrane stabilizing activity (MSA). This effect is similar to the action of 
sodium-channels blockers (www.cvpharmacology.com) and hence this class 
of compound is also useful for antiarrhythmic effects. 
Propafenone treatment is flexible as it can be used for both short and long 
term treatment of arrhythmias and can be administered both orally and 
intravenously. Intravenous administration is effective for ventricular 
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arrhythmias whereas an oral dose is an effective form of management of 
chronic re-current supraventricular tachycardia (Musto et al, 1988). 
 
1.3. Racaemic drugs 
As mentioned earlier propafenone is a chiral compound (Fig 1.2) which is 
predominantly administered as a racemate and at a dosage of between 300 - 
450mg/ml (Jazwinski et al, 2001). When using chiral drugs it has been shown 
that stereoselectivity of one or more pharmacological activities may occur with 
the difference in activity being up to as much as 100 fold (Mehvar et al, 2002). 
Furthermore, the use of racaemic antiarrhythmic drugs can be problematic 
with regards to their metabolism which may vary between different 
enantiomers. This may be especially problematic when the drug metabolism 
is genetically/phenotypically dependent and/or active metabolites are 
generated (Ha and Follath, 2004). It has been established that both 
enantiomers of propafenone exert similar sodium channel blocking abilities,  
but further research has shown that it is the (S) - enantiomer that produces 
greater Beta adrenoceptor blocking capabilities (Kroemer et al, 1994). 
Research into racemate drug therapy is therefore vital as the two individual 
enantiomers can exert different pharmacological properties and so do not 
reflect the same action as the racemate. It is important to look at the individual 
activities of the enantiomers and the interactions between them when given 
as a racaemic mixture as they could in fact prove to be more effective 
individually or potentially dangerous. Such is the case with thalidomide where 
the (S)-enantiomer caused the teratogenicity whilst the (R)-enantiomer acted 
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as a sedative (Anderson, Richardson and Alsina, 2003). Furthermore in this 
case, the use of separate enantiomers failed as they could interconvert in the 
body (Anderson, Richardson and Alsina, 2003). In fact it has been proposed 
that racaemic drugs should be avoided altogether (Kroemer et al, 1994).  
There are many variables that can affect a drug’s efficacy; for example 
whether its metabolism is inhibited by its opposite enantiomer (Kroemer et al, 
1994) or another drug, or how the drug itself inhibits the body’s enzymes and 
the effects of the drugs metabolites It is vital to discover these variables and 
the best way to minimise or eliminate them to ultimately improve a patient’s 
health. 
In particular, research into differences in drug metabolism is vital to determine 
possible side effects of drugs during the process of drug development. The 
metabolic pathway(s) for the drug needs to be fully understood as it will play 
an important factor in determining the pharmacological or toxicological effects 
(Gibson and Skett, 2001). Indeed, as will be discussed later, the activity of 
metabolising enzymes determines the plasma concentrations and therefore 
the associated effects of the drug (Botsch et al, 1993) and this information can 
be invaluable in determining the interactions of the drugs, variability and 
effectiveness. 
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Figure 1.2 The structure of propafenone, where the red circle represents its 
chiral centre. 
 
1.4. Factors that affect plasma concentration. 
The pharmaceutical effectiveness of a drug is dependent upon its 
concentration at its site of action. The processes which determine changes in 
the concentration of a drug in the body can be subdivided into four discrete 
areas. These are the processes of absorption, distribution, metabolism and 
excretion which will be discussed below. It is the combined effect of these 
processes which determine the shape of the plasma concentration – time 
curve illustrated in Figure 1.4. These factors will determine how long a drug 
will be present in the body which is often expressed as the half life of the drug 
(t½) which is the time taken for plasma concentration of the drug to fall by half. 
Propafenone has an elimination half life of approximately 2 – 10 hours 
increasing to as high as 32 hours in poor metabolisers. (Jogler et al,1998). As 
the work described here concentrates in particular on the drug metabolism 
process; this will be discussed in more detail. 
The term ‘therapeutic window’ is used to describe the plasma concentration 
range at which a drug is effective with minimal adverse reactions. The 
therapeutic window lies between two regions. The lower one represents the 
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lack of drug and therefore its ineffectiveness. The upper region is an over 
exposure resulting in the therapy being effective but producing adverse 
effects, therefore the therapy has failed. Propafenone is one of a number of 
drugs for which the therapeutic window is narrow and hence relatively small 
changes in plasma concentration can lead to ineffectiveness/toxicity. The 
result of this can be seen with the situation in 2008 when Watson 
Pharmaceutical had to recall a batch of propafenone tablets whose size 
varied sufficiently to alter plasma concentration. Patients who were sensitive 
to small variations in dosage may have experienced serious side effects. 
(www.fda.gov) 
 
Figure 1.3 A diagrammatic representation of a wide and narrow therapeutic 
window. (www.vin.com).  
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Figure 1.4. Plasma concentration–time relationship after a single oral dose of 
a hypothetical drug. (www.merck.com) 
 
1.4.1. Absorption 
A compound needs to be absorbed into the bloodstream before its 
pharmacological effects can occur. There are several factors that affect the 
absorption of a drug after oral administration, for instance the compounds 
solubility, permeability and its chemical instability. In large part absorption of a 
drug is determined by the compounds bioavailability. Bioavailability is a 
relative term used to describe the rate and extent of absorption after oral 
administration of a drug (Kwon, 2001).The extent of bioavailability is governed 
by factors such as the absorption from the gastrointestinal tract and 
metabolism that occurs before absorption takes place. The absorption of 
propafenone is extensive and rapid with a peak plasma concentration 
occurring after approximately 3.5 hours’ (www.GSK.com). The issue of 
bioavailability of drugs is important in determining their therapeutic 
effectiveness and an estimation of bioavailablilty can be made using Lipinski’s 
‘rule of five’. This indicates whether a drug is likely to be orally bioavailable. 
The rules specify that the drug will have more than 5 hydrogen bond donors, 
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no more than 10 hydrogen bond acceptors, and a molecular weight under 500 
and a LogP under 5. (www.bioscreening .com)The process of absorption can 
occur via several routes, which include passive diffusion, facilitated diffusion 
and active transport. Simple diffusion of a drug across the cell membrane, it is 
a process driven by the random motion of the molecules. Diffusion is 
described by Fick’s law, which states that diffusion is proportional to the 
concentration gradient (Washington et al, 2000). The difference in 
concentration is maintained by the continual removal of the drug from the 
blood to tissues. It is also dependant on the drug’s lipid solubility and the 
degree of ionization and its size. The process of facilitated diffusion and active 
transport both require the presence of a carrier molecule which combines with 
the drug molecule and allows it to cross the bilayer. This is evident from the 
transport of molecules such as glucose which has low lipid solubility, and this 
action is selective as it will only allow the movement of molecules with a 
specific molecular configuration and the availability of the carriers. Facilitated 
diffusion does not require energy and similarly to passive diffusion, movement 
is dependant on a concentration gradient from high to low. An example of this 
is the movement of sodium into the cardiac cells via a carrier protein which 
exchanges sodium for calcium (Sparks, 1987). The process of active transport 
utilises energy in the form of ATP to pump molecules across a membrane 
against a concentration gradient.  An example of this is Na+, K+ ATPase 
which expels three sodium ions for every two potassium ions that move into 
the cell, this movement is possible through the energy form ATP (Sparks 
1987). In addition, P Glycoprotein transporters found in the gastrointestinal 
membrane can use the process of active transport to pump drugs back out of 
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the body into the gastrointestinal lumen. There is an overlap between the 
substrates of P Glycoprotein and CYP3A4, therefore the drugs that inhibit or 
induce CYP3A4 do the same to P Glycoprotein and consequently affect 
transportation (Troy and Beringer, 2005) 
 
Figure 1.5. Diagram illustrating the three major processes involved in the 
passage of molecules across the plasma membrane lipid bilayer. 
(www.rpi.edu) 
 
1.4.2 Distribution 
For a drug to have its desired therapeutic effect it is necessary to be 
distributed in such a manner that a sufficient concentration reaches its site of 
action. The process of drug distribution is dependent on the physicochemical 
properties of the drug which can affect how drugs will partition throughout the 
different fluid compartments within the body. In addition, the distribution of 
drugs is influenced by their binding to proteins found within both the blood 
plasma and the tissues. An estimation of the distribution of the drugs can be 
made by calculating the apparent volume of distribution which is mathematical 
in concept defined as the distribution of a drug between the plasma and the 
 14 
rest of the body. The Vd for propafenone averages between 2.5 – 4.0 L/Kg 
(Kerns et al, 1994). 
1.4.2.1 Protein binding 
Binding to proteins plays an essential role in the transport and distribution of 
drugs and it is a function of the affinity of the protein to the drug. Plasma 
protein binding is mainly to the protein albumin which possesses binding sites 
for both endogenous and exogenous compounds. The two major binding sites 
are known as the warfarin-azapropazonesite and the indole-benzodiazepine 
site (Cheng et al, 2004). The affinity is characterised by an association 
constant and because of the limited binding sites binding also depends on the 
concentration of the drug and protein (Rowland and Tozer 1995). Drug-protein 
binding may also occur with the protein alpha 1 acid glycoprotein (AGP). AGP 
has the ability to bind and carry many basic and neutral lipophillic drugs as 
well as acidic drugs such as Phenobarbital (Fournier et al, 2000). AGP is an 
acute phase plasma protein synthesized in the liver. Its concentration in blood 
plasma is increased in time of trauma and can be used to diagnose 
inflammatory conditions. The exact mechanism of inflammatory and immune 
responses is unknown at this time (Gunnarsson et al, 2007). 
The degree of protein binding is an important factor as it is the unbound drug 
which is free to determine the pharmacological activity as well as undergo 
processes such as metabolism excretion and disposition. Propafenone is 
highly protein bound usually around 95%. Therefore, the higher affinity a drug 
has for the protein the slower the disassociation rate will be therefore lowering 
clearance and increasing the elimination half life (Sear, 2007). The degree of 
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binding to the individual enantiomers could affect their pharmacological 
properties by altering the amount of free drug available. Therefore quantitative 
determination of drug protein binding is important in drug development 
(Cheng et al, 2004). 
1.4.2.2 Tissue binding 
Tissue binding can also play a role in the distribution of drugs. There have 
been less studies of tissue binding conducted in comparison to plasma protein 
binding perhaps because it is more difficult to measure, and also it requires 
that tissue has to be disrupted and therefore loses its integrity (Rowland and 
Tozer, 1995). The primary effect of tissue binding is on the time period of the 
drug within the body, as it can increase the half life of the drug. 
 Furthermore, non-specific tissue binding is an important factor to be 
considered when conducting in vitro experiments (such as the drug 
metabolism work conducted here) as this can lead to the drug concentration 
to be underestimated (Austin et al, 2002) 
 
1.4.3 Drug metabolism. 
The process of drug metabolism is central to the excretion of drugs form the 
body. In general terms drug metabolites are more hydrophilic than their parent 
drug which decreases their reabsorption from the tubules of the kidney back 
into the body hence increasing their excretion. In addition, the structural 
changes caused by drug metabolism can, in many instances, decrease the 
pharmacological activity of the drug. Although this need not always be the 
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CONJUGATE 
case with many drug metabolites showing equipotent or even greater 
pharmacological activity to the parent drug. Drug metabolism can be 
subdivided into two main phases: phase 1 and phase 2. Phase 1 involves the 
oxidation, reduction or hydrolysis of the drug with the majority of reactions 
being catalysed by the cytochrome P450 family of enzymes (Fig 1.6). This 
process generally makes the drug more reactive by introducing/unmasking 
chemically reactive groups and in doing so, may makes the drug more toxic or 
even more pharmacologically active (Gard, 2001). Phase 2 metabolism 
involves the addition of a conjugate to the molecule (Gibson and Skett, 2001) 
(Fig 1.6). Phase 2 metabolism requires a functional group which may be 
present on the original drug or is very often added or exposed during phase 
one metabolism (Fig 1.7). The function of phase 2 metabolism is to increase 
the water solubility of the compound hence increasing its excretion by 
decreasing the process of urinary reabsorption (Fig 1.6). 
 
     DRUG                   PHASE 1           METABOLITE PHASE 2    
 
 
 
 
   
Figure 1.6. Diagrammatic representation of the metabolism of drugs via 
Phase I and Phase 2 processes. The overall process results in the 
metabolites becoming more polar than the original drug. 
Renal excretion Biliary Elimination 
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Figure 1.7 Shows examples of phase 2 reactions  
 
1.4.4 Excretion 
Excretion is the irreversible loss of a chemically unchanged drug and occurs 
predominantly via the kidney with biliary excretion being the second most 
common route (Tozer and Rowland, 2006). Propafenone is almost entirely 
metabolised in the liver with only 1% of the drug being excreted unchanged 
(Jogler et al, 1998). 
 
1.5 Cytochrome P450 
The cytochrome P450 (CYP) family of enzymes are the major contributors to 
Phase 1 metabolism (Kwon, 2001).They are a superfamily of heme containing 
enzymes found in the endoplasmic reticulum of the cell. CYPs are found in 
high quantities in the liver although they are also found in other organs 
throughout the body such as the kidney, breast and gastrointestinal tract. 
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(Ioannides,1996). Cytochrome P450 was first mentioned in literature in 1962 
when liver microsomes (which are a suspension of the endoplasmic reticular 
fraction of the cell) were treated with dithionite (a reducing agent) and carbon 
monoxide gas which binds to the reduced ferrous heme of the Cytochrome 
P450 enzymes present to give a strong absorption band at 450nm. This is 
known as a reduced carbon monoxide difference spectrum, and it is this 
characteristic absorption which gives rise to the 450 element of their title, 
where the ‘P’ represents the pigment (Omura, 1999). Absorbance at 450 nm 
is significant as no other heme containing protein produces an absorbance at 
450nm. 
 
 
 
 
Figure 1.8. The molecular structure of Cytochrome P450 showing the heme 
moiety and associated Fe atom. (www.esrf.eu) 
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The overall process of CYP catalysed metabolism is represented in figure 1.9. 
The process can be summarised as CYP splitting molecular oxygen and using 
one atom for the generation of the metabolite and the other for the production 
of water. In order for Cytochrome P450 to function they need a source of 
electrons added to the heme iron for the catalytic cycle to occur. The 
electrons are donated by another protein in the endoplasmic reticulum called 
NADPH cytochrome P450 reductase. There is, therefore a requirement of 
NADPH for CYP activity both in vivo and in vitro (Mathews et al, 2000; Fig 
1.10). 
RH + O2 + NADPH +H+  ROH + H2O + NADP+ 
Figure 1.9 General equation for the metabolism (oxidation) of a substrate 
(RH) by Cytochrome P450.  
 
 
Figure 1.10 Oxidation of foreign compounds by Cytochrome P450 (Gilham et 
al 1997)  
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When considering the metabolism of drugs by CYP it is important to realise 
that a drug can be metabolised by one or multiple CYPs and that it is the 
affinity of the drug to the enzyme and the abundance of the enzyme in the 
body which affect the rate of metabolism this is important with regards to the 
inhibition study. (www.Cytochrome P450 Enzymes and 
Psychopharmacology.htm) 
 
1.5.1 Classification of CYP 
As there are so many different isoforms of P450 it is important to be able to 
differentiate between them. Classifying them in relation to their amino acid 
sequence allows this differentiation to occur (Kelly et al, 2006). CYP isoforms 
are divided into families and subfamilies with the family accounting for genes 
which possess at least 40% sequence homology (Ioannides, 1996). Families 
are symbolised with numbers whereas the subfamilies are identified using 
letters and must have at least 55% sequence homology (Nerbert and 
Gonzalez, 1987). In addition to this individual genes are identified with a 
number, for example CYP2D6. 
To date, 57 CYP genes and 58 pseudogenes have been sequenced in 
humans. The most abundant form of CYP is CYP3A4 which makes up 
approximately 30% of the total P450 composition of tissues (Plant and 
Gibson, 2003). The CYP 3A family has been identified as the major 
cytochrome P450 expressed in the liver at all developmental stages and 
CYP3A4 has been proven to be responsible for up to 60% of the metabolism 
of pharmaceuticals (Gibson and Skett, 2001). The CYP2 family is the largest 
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family in humans and one third of all human P450’s are in this family 
(www.drnelson.utmem). CYP2D6 is studied extensively as it is polymorphic 
and metabolises many drugs including anti-depressants and opioids (Chen 
and Wei- Min, 2003). 
CYP1A2 is very important as it can be induced by polycyclic hydrocarbons 
found in cigarette smoke and it can metabolise compounds to become 
carcinogenic e.g. benzo (a) pyrene and has been associated with colon 
cancer (www.drnelson.utmem; Johns-Cupp, 1998). 
As cytochrome P450 enzymes have such a central role in drug metabolism it 
follows that any change in CYP activity may have a profound effect on the 
concentration of a drug in the body, and so the pharmacological and 
toxicological effects. There are a number of factors which can influence CYP 
activity which are summarised below. 
 
1.5.2 Factors Affecting Cytochrome P450 Activity 
Genetic polymorphism is a difference in DNA sequence in a particular gene 
found at 1% or higher in a population. These differences lead to changes in 
drug metabolism when there are several metabolic phenotypes. There are 
usually two main phenotypes which result in the distinction between fast and 
slow metabolisers (Funckbrentano, 1991). This difference is subject to ethnic 
variability for example in caucasians the polymorphism of CYP2C19 for the 
poor metaboliser phenotype is only seen in 3% of the population whereas in 
the Asian population it can be seen in 20% (www.drnelson.utmem). Therefore 
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it is important to be aware of a persons race when drugs are administered that 
are known to be metabolised differently by different populations. It is now 
possible to determine what type of metaboliser a person is. In terms of 
progression this is an important step as CYP1A2, 2C19, 2D6 and 3A4 are 
responsible for oxidising more than 90% of currently used drugs.  
1.5.3 Age 
Drug metabolism can be affected by the age of the individual. It is generally 
the case that the young and the old have a lower drug metabolising capacity. 
(Gibson and Skett 2001). In men and women over the age of 65 the ability to 
metabolise drugs declines as does the amount of the relevant cytochrome 
P450 (Gibson and Skett, 2001). Age can have an affect on drug metabolism 
due to a reduction in liver volume and a reduction in the activity of some 
CYP’s. It has been proven however that there is reduced activity of CYP1A2 
and CYP2C19 with age. It has also been suggested that the inducibility of 
metabolising enzymes decreased with age (Kinirons and O’Mahony, 2004). 
1.5.4 Drug interactions. 
The risk of having an adverse reaction increases with the number of drugs 
taken. A drug interaction occurs when the pharmacodynamics or 
pharmacokinetics of one drug are altered by another. The extent of the 
interaction is dependant on the dose and time (Rowland and Tozer, 1995). 
The use of in vitro studies has several advantages for example the savings on 
cost and time of as well as minimization of human risk due to the planning and 
design of clinical studies. 
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1.5.4.1 Induction 
Induction can be defined as an increase in the transcription and hence the 
levels and activity of metabolising enzymes. Examples of known inducers of 
CYP are shown in Table 1.2. A number of drugs have been shown to increase 
their own metabolism as well as the metabolism of co- administered drugs via 
the process of induction. Due to the mechanism involved in induction, this 
process is not instantaneous, but has a time lag before the increase in 
enzyme level is observed. However, the induction of drug metabolism does 
have significant clinical importance as increased metabolism can lead to a 
decrease in plasma concentrations of drugs which may render them 
ineffective. For example the treatment of phenobarbitone and its effect on the 
muscle relaxant zoxazolamine. Zoxazolamine undergoes metabolic 
hydroxylation which forms an inactive metabolite. The increase in the 
metabolism of the muscle relaxant in turn decreases the paralysis time of the 
drug (Gibson and Skett, 2001). 
Table 1.2 The CYPs used in this study and examples of their known inducers 
(www.medicine.iupui.edu) 
CYP1A2 CYP2D6 CYP2C19 CYP3A4 
Omeprazole Rifampin Rifampin Phenobarbital 
Tobacco Dexamethasone Carbamazepine Rifampin 
Insulin Piperidines Norethindrone Carbamazepine 
Nafcillin Carbamazepine Prednisone Barbiturates 
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1.5.4.2 Inhibition 
The inhibition of metabolic processes is extremely important in terms of 
possible therapeutic problems associated with drug-drug interactions (DDIs). 
In this case, the inhibition process can lead to accumulation of drug in the 
body which may reach toxic levels. Indeed, for cytochrome P450 enzymes, 
many drugs have been found to cause inhibition which has restricted their use 
due to the potential for sever DDIs (Li et al, 2007). The process of inhibition 
can be either competitive or non competitive in nature although in the majority 
of cases it is competitive inhibition which is observed. A number of clinically 
relevant inhibitors of cytochrome P450 are shown in Table 1.3.  
An example of DDI is the interaction of felodipine with grapefruit juice. CYP3A 
present in enterocytes of the intestinal epithelium extensively metabolise 
felodipine during its absorption allowing only 30% of the administered dose to 
enter the portal vein. CYP3A enzymes in the liver further metabolise the drug 
so that only 15% of the dose is bioavailable and can exert its effect. Grapefruit 
juice selectively inhibits CYP3A in the enterocyte therefore increasing the oral 
bioavailability of felodipine by a factor of 3 (Wilkinson, 2005). 
This example shows the clinical importance of identifying inhibitors of specific 
CYP’s and the associated drug interactions in order to prevent the inability to 
metabolise the drug. 
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Table 1.3 The CYPs used in this study and examples of their known inhibitors 
(www.medicine.iupui.edu) 
CYP1A2 CYP2D6 CYP2C19 CYP3A4 
Fluvoxamine Fluoxetine Omeprazole Erythromycin 
Cimetidine Quinidine Fluoxetine Verapamil 
Furafyline Omeprazole Oxcarbazepine Ketoconazole 
Interferon Cimetidine Ticlopidine Diltiazem 
 
1.5.5 Metabolism of propafenone 
Propafenone has been reported to be metabolised by CYP2D6 to 5-
hydroxypropafenone and to N-depropyl-propafenone by CYP3A4 and 1A2; 
which is the minor pathway in comparison the one mediated by CYP 2D6 
(Yong-Jiang and Ming-Ming, 2004) (Fig 1.11). Phase 2 metabolism is 
predominantly via the generation of the glucuronide.  Compared to 
propafenone, the main metabolite, 5-hydroxypropafenone, has similar sodium 
and calcium channel activity, but about 10 times less beta-blocking activity (N-
depropyl-propafenone has weaker sodium channel activity but equivalent 
affinity for beta-receptors).  
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Figure 1.11 The two main metabolic pathways of propafenone and the 3 
cytochrome P450’s which are responsible for the catalytic process (Labbe et 
al, 2000, Munoz et al, 1997). 
 
 The majority of studies on the metabolism of propafenone have concentrated 
on the involvement of CYP2D6 with an emphasis on investigating the effect of 
CYP2D6 polymorphism on the therapeutic efficacy of propafenone. It has 
been found that there is interindividual variability in the pharmacokinetic and 
pharmacodynamic characteristics of propafenone resulting from the genetic 
polymorphism found with CYP 2D6 (Wei et al, 1999) (where around 7% of the 
white population have been shown to be poor metabolisers) (Siddoway et al, 
1987; Dilger et al, 2000). It was also found that propafenone therapy was 
100% effective in controlling arrhythmias in poor metabolisers and only 61% 
effective in extensive metabolisers (Jazwinski et al, 2001). 
Furthermore, research on the metabolism of propafenone and its effects with 
the co-administration of the CYP 2D6 inhibitor quinidine has demonstrated an 
importance of this enzyme in the metabolism of propafenone. Indeed, 
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quinidine has been shown to increase the plasma concentration of 
propafenone in extensive metabolisers (Morike and Roden, 1994). 
It has also become clear that there is significant interaction between both (R) 
and (S)-propafenone. With regards to their metabolism, the (R)-enantiomer 
can inhibit the metabolism of (S)-propafenone (Pires de Abreu et al, 1999). 
This study has indicated that the effects of racaemic drug therapy cannot 
simply be deduced through the effects of the individual enantiomers as the 
beta blocking effects of (S)-propafenone were more pronounced when 
administered as a racemate rather than individually. 
In addition when the metabolism of propafenone is reduced it creates a higher 
concentration of (S)-propafenone to exist. As (R)-propafenone inhibits the (S)-
enantiomer which exhibits the higher beta blocking effect.  
The following study will show the extent of metabolism of propafenone via 
these pathways but it will also include CYP2C19 which tends to be studied to 
a lesser degree than the other major form of cytochrome P450 (Turpeinen et 
al, 2006). 
 
1.6 Methods Used in This Study 
1.6.1 Investigation of the Activity of Cytochrome P450 in vitro 
There are a number of techniques which can be used to investigate the 
activity of CYP enzymes, their interactions with different substrates and the 
propensity for DDIs. These are outlined in Table 1.4. 
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In this study, heterologous CYP expression system (cDNA expressed human 
drug metabolising enzymes) will be used for conducting in vitro inhibition 
studies (bactosomes, Cypex). This system is utilised rather than microsomes 
as the bactosomes contain only one CYP isoform as opposed to a mixture of 
enzymes found in hepatic microsomes. This was chosen in order to determine 
which CYP is inhibited to the greatest degree by propafenone and, when 
incubated with an individual bactosome, which one metabolises propafenone 
the most. By doing this the individual bactosomes can be compared and it is 
possible to deduce which CYP isoform propafenone (racemate and 
enantiomers) shows greatest interaction. The bactosomes chosen for the 
inhibition and metabolism studies are CYP3A4, CYP2D6, CYP2C19 and 
CYP1A2. 
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Table 1.4 The methods employed to investigate the activity of CYPs and drug 
metabolism (Tingle and Helsby, 2005) 
Method Advantages Disadvantages 
Animal models 
 Physiologically 
relevant. Can identify 
metabolites formed. 
 Provides information 
on clearance by 
multiple enzymes and 
organs. 
 Information on drugs 
that don’t undergo 
hepatic clearance. 
 Can show what is 
biologically possible not 
necessarily what is 
relevant for humans. 
 Inter-species differences 
in drug metabolism 
Human liver microsomes 
(HLM) 
 Allows CYP reaction 
phenotyping- to identify 
undesirable DDIs 
 Qualitative 
determination of 
metabolite identity 
 Used for prediction of 
in vivo clearance 
 Substrate depletion 
approach can be 
utilised. 
 This approach is limited 
technically due to non-
specific binding of the 
drug to microsomal 
protein. 
 Concerns over the 
appropriate drug 
substrate concentration 
 Requires prior knowledge 
of the metabolic fate of 
the drug 
cDNA expressed human drug 
metabolising enzymes. 
 Widely used to 
determine the 
individual CYP involved 
in the metabolism of a 
drug. 
 Limited by the 
immunodetection and 
quantification of CYP in 
the liver 
 Not all CYPs are 
available. 
 Used to study a single 
metabolic phase and 
don’t take into account 
sequential metabolic 
routes. 
Hepatocytes 
 Has the ability to 
examine phase 1 and 2 
metabolism. 
 Allows identification of 
drug inducers and toxic 
metabolites. 
 Issues concerning donor 
availability. 
 Changes in enzyme 
activity after isolation. 
 Inter individual 
differences between 
donors. 
 Accuracy and validity 
requires assessment of 
more compounds. 
Liver slices 
 Has the potential to 
give better 
qualitative/quantitative 
data for the metabolic 
fate of a drug. 
 More complicated 
system than HLM – 
similar predictive 
qualities. 
 Limited availability 
 Donor variability 
 Require specialised 
equipment 
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1.6.1.2 Use of inhibition studies to investigate CYP interactions in vitro 
The importance of recognising drug-drug interactions at the level of drug 
metabolism to predict possible severe clinical problems has led to the 
development of methods to measure CYP inhibition in vitro.  These 
techniques have been adopted by the pharmaceutical industry as a high 
throughput screen for new chemical entities at early stage development. This 
method has proven to be extremely useful in drug discovery, as in the 1990’s 
guidance documents were issued from regulatory agencies in relation to the 
assessment of in vitro inhibition of the major CYP enzymes. 
Therefore this method enables pharmaceutical companies to predict CYP 
mediated drug-drug interactions early in drug development (Yao et al, 2007). 
The methods rely upon the use of standard enzyme substrate and their 
inhibition by the compounds of interest. The technique employed in this study 
has previously been used to determine the involvement of single or multiple 
enzymes in the metabolism of a drug through an inhibitory assay (Turpeinen 
et al, 2006). 
The following section describes the basis of enzyme inhibition which is central 
to the technique used here for the investigation of propafenone interaction 
with different CYP isoforms. 
 
1.6.1.3 Enzyme structure and substrate binding 
Each enzyme has active sites which are three dimensional made up of groups 
of amino acid sequences. Substrate binding to these sites creates the enzyme 
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- substrate (ES) complex. In reversible reactions the substrate is bound by 
forces such as electrostatic, Van Der Waals or hydrogen bonds. 
This mechanism was discovered by Emil Fischer and his Lock and Key 
system (Mathews et al, 2000; Fig 1.12). 
 
Figure 1.12. The lock and key mechanism. 
(www.neurobio.drexel.edu) 
 
Later the induced fit model was developed as shown in figure 1.13 the 
difference is that the enzymes active site changes to complement the 
substrate after it has bound (Mathews et al, 2000). 
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Figure 1.13 The mechanism of the induced fit model an extension of Fischer’s 
previous idea. (www.neurobio.drexel.edu) 
 
It is known now from the work of Leonor Michaelis and Maud Menten that the 
rate of catalysis (V) increases with the concentration of the substrate (S) when 
the concentration of the enzyme (E) is constant (www.chm.davidson.edu). 
This is true when the concentration of the substrate is low, when [S] becomes 
in excess of the enzyme concentration the situation changes where V is 
indirectly proportional to the concentration of the substrate. 
Due to this observation Leonor Michaelis and Maud Menten deduced the 
following equation (Fig 1.14) which also defined the constants Km and Vmax 
also known as the Michaelis constant and is equal to the substrate 
concentration at which the reaction rate is half its maximal value. A high Km 
indicates a weak binding, and a low Km indicates strong binding (Matthews et 
al, 2000). Therefore the lower the Km the stronger the bond between the 
substrate and the enzyme. Vmax or maximum velocity occurs when the 
enzymes are saturated i.e. every enzyme molecule is occupied by substrate 
and carrying out the catalytic step and so an increase in substrate 
concentration does not increase the rate of catalysis (Mathews et al, 2000). 
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Figure 1.14 The Michaelis-Menten equation. 
 
1.6.1.4 Enzyme Inhibition 
This study deals with competitive inhibition, where the enzyme binds to either 
the substrate or the inhibitor (but not both). In general, the inhibitor exhibits a 
similar form to the substrate and this is why an enzyme – inhibitor (EI) 
complex can be established. A competitive inhibitor therefore reduces the rate 
of catalysis as the number of ES complexes formed decreases and EI 
complexes increase (Shou et al, 2000). This can be overcome if the 
concentration of the substrate increases to greater than that of the inhibitor. 
When competitive inhibition is occurring Vmax does not change as inhibition 
can be overcome if the substrate concentration is increased sufficiently 
(Mathews et al, 2000). The efficacy of an inhibitor can be measured through 
its IC50 which is the inhibitor concentration at which 50% of the enzyme 
activity is inhibited (Francke et al, 2002).  IC50 values are derived by plotting 
the percent of activity remaining with regards to increasing inhibitor 
concentrations (Fig 1.15). IC50 values are intrinsically linked to binding affinity 
for competitive agonists and antagonists through the equation shown in 
Figure 1.16. 
 
 
[S] + Km 
V =  Vmax 
[S] 
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Figure 1.15 Determination of IC50 values from an inhibitor concentration vs. 
enzyme activity plot (www.spotlite.nih.gov) 
 
 
     
 
 
Figure 1.16 Relationship between IC50 and the binding affinity of the inhibitor 
(Ki) (Cheng-Prusoff equation)  
 
Determining IC50 values for the interaction with CYP isoforms will therefore 
give information as to relative binding affinities and propensity for in vivo drug-
drug interactions. 
 
1.6.2 Protein binding. 
The measurement of protein binding is, as has been described in section 
1.4.2.1, central to understanding the disposition of drugs in the body. A 
protein binding study is important as it is the unbound drug that is free to exert 
 Ki  =  IC50 
  
1 + [S]/Km 
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its pharmacological effects, therefore if it is determined that the enantiomers 
have a greater degree of binding than the racemate it is vital to know. Many 
critical pharmacokinetic parameters are a function of unbound drug fraction. 
Therefore quantitative determination of drug protein binding is important in 
drug development (Cheng et al, 2004). 
There are a variety of techniques available for measuring protein binding 
including ultrafiltration and equilibrium dialysis (Kwon, 2001; Crommelin et al, 
2002). In this study the use of a chromatographic method using a column 
containing Human Serum Albumin (HSA) will be used to determine and 
compare the protein binding of propafenone in its racemate form and its 
individual enantiomers. The next step will be to determine the binding of other 
compounds and compare to published data, as this will show that results 
obtained are indicative of protein binding. 
 
1.6.3 In vitro metabolism. 
The metabolism of compounds by CYP isoforms can be conveniently 
measured in vitro. This requires the use of a metabolising system (containing 
CYP) co-incubated in buffer with the compound of choice. It then remains to 
measure the removal of compound from the incubation and/or the production 
of metabolites.  
To determine the extent of in vitro metabolism this study will utilise HPLC. 
(high performance liquid chromatography) to separate propafenone from its 
metabolites. Chromatography is characterised as a series of techniques that 
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are used to separate multiple components in a samples based on relative 
affinities of these components between the mobile phase and the stationary 
phase (Sadek, 2004). 
HPLC involves four basic components, the injector, mobile phase, stationary 
phase and the detector (Fig 1.17) 
 
  Figure 1.17 Components of a HPLC system (www.protein.iastate.edu) 
 
The premise of HPLC is that the analyte is contained in a liquid known as the 
mobile phase and is pumped through a stationary phase. One phase is 
hydrophilic and the other lipophillic (in reversed phase HPLC it is the 
stationary phase which is lipophillic). The time spent interacting with the 
stationary phase is dependent on the analyte’s polarity. This process causes 
a separation of the sample, the time the analyte elutes from the stationary 
phase (retention time) is specific. When this occurs the analyte passes 
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through the detector where its signal is recorded and plotted on a 
chromatograph (Manz et al, 2004). 
The mobile phase used in HPLC is under high pressure which maintains a 
constant flow rate and in allows for reproducibility. The mechanism of 
separation is concerned with the relative affinity of the analyte to the mobile 
and stationary phases which determines the retention time of the analyte. 
The percentage metabolism occurring in each test will be deduced in 
comparison to the control from the data collated on the chromatographs. It will 
determine if the enantiomers are metabolised to a greater extent or not, which 
is an important step in drug development. In general the metabolites are more 
polar than the parent compound and so reversed phase HPLC is ideal for the 
separation process. 
 
By using these various techniques it is possible to gain an insight into the 
interactions which will determine a drug’s in vivo disposition. As previously 
mentioned, this study will look at the development of these techniques to 
investigate stereospecific differences with the racaemic antiarrhythmic drug 
propafenone. 
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2. Materials and methods. 
2.1 Materials 
Propafenone and its enantiomers were obtained from Knoll AG 
(Ludwigshafen, Germany). The bactosomes CYP 1A2, CYP3A4, CYP2C19 
and CYP2D6 were purchased from Cypex (Dundee, Scotland). Human liver 
microsomes were obtained from Advancell (Barcelona, Spain). All chemicals 
used were bought from Sigma Aldrich (Gillingham, Dorset) 
2.1.1 Buffers and stock Solutions 
Phosphate buffer (0.5M) was prepared by dissolving 3.40 g of potassium 
phosphate monobasic salt and 4.35 g of potassium phosphate dibasic salt in 
50 ml of deionised water. A volume of 7.5 ml was taken from the 0.5 M 
potassium phosphate monobasic and mixed with 35.0 ml of 0.5 M potassium 
phosphate dibasic to generate the final buffer with a pH of 7.4 (42.5 ml). From 
this solution 0.2M, 0.1M, 0.05M and 0.02M dilutions were made.  
2.1.2. Preparation of cofactors. 
The cofactors for CYP3A4, CYP2C19 and CYP1A2 experiments (20x stock) 
were made by weighing 200 mg NADP+ (20 mg/mL), 200 mg glucose-6-
phosphate (20 mg/mL) and 133 mg magnesium chloride hexahydrate (13.3 
mg/mL), these three components were then dissolved in a volume of 10 mL of 
deionised water. For CYP2D6 experiments (160x stock) the cofactor was 
made up as above using 1.60 g of NADP+. 
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2.1.3. Preparation of glucose-6-dehydrogenase  
A weight of 200 mg of glucose-6-dehydrogenase was dissolved in 10 mL of 
deionised water. 
2.1.4. Preparation of propafenone (10mM) 
A weight of 37.8 mg of propafenone was dissolved in 10 mL of deionised 
water. It was then sonicated for 5 minutes to ensure complete dissolution. 
2.1.5. Preparation of ketoconazole (0.25mM) 
A weight of 0.266 mg of ketoconazole was dissolved in 20 mL of deionised 
water. 
 
2.2 Preparation of the Cofactor Mixtures. 
Cofactor mixtures for the production of NADPH were produced as follows. 
2.2.1 CYP3A4 Assay. 
A volume of 1.8 mL of 0.5 M phosphate buffer (2.1.1) was added to 90 µL 
glucose-6-phoshate dehydrogenase (2.1.3), 450 µL of cofactors (2.1.2) and 
2.16 mL of deionised water. 
2.2.2 CYP2C19 assay. 
A volume of 450 µL of 0.5 M phosphate buffer (2.1.1) was added to 90 µL 
glucose-6-phoshate dehydrogenase (2.1.3), 450 µL of cofactors (2.1.2) and 
3.51 mL of deionised water. 
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2.2.3 CYP1A2 assay. 
A volume of 2.0 mL of 0.5 M phosphate buffer (2.1.1) was added to 100 µL 
glucose-6-phoshate dehydrogenase (2.1.3), 125 µL of cofactors (2.1.2) and 
7.78 mL of deionised water. 
2.2.4 CYP2D6 assay. 
A volume of 700 µL of 0.5 M phosphate buffer (2.1.1) was added to 70 µL 
glucose-6-phoshate dehydrogenase (2.1.3), 88 µL of cofactor mixture (2.1.2) 
and 6.15 mL of deionised water 
 
2.3 Measurement of NADPH Production by Regenerating System. 
2.3.1 Generation of the NADPH standard curve  
A stock solution of 1mM NADPH in a volume of 10 ml was made by dissolving 
0.833 mg NADPH in deionised water which was diluted 1 in 5 to give a 
second stock of 200 µM in 5 mL. From these solutions the following working 
standards were prepared. 500 µM, 250 µM, 125 µM, 100 µM, 50 µM and 25 
µM (each incubation contained 100 µL). 
The incubation for the NADPH standard curve was measured at an 
absorbance of 580 nM for 10 minutes using a clear bottomed plate.  
2.3.2 Measurement of NADPH production 
A volume of 700 µL 0.5M phosphate buffer (2.1.1) was added to 88 µL of 
cofactor mixture (20 x solutions 2.1.2) and 6.15 mL of deionised water. 98 µL 
of this mixture was pipetted into the plate and preheated in the plate reader at 
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37ºc. Finally a further 2 µL of Glucose-6- phosphate dehydrogenase (2.1.3) 
was added and the absorbance was measured at 580nm for 5 minutes using 
the Tecan Genios Pro plate reader. 
 
2.4. Cytochrome P450 activity and IC50 of Inhibitor and Propafenone 
High throughput method for determining Cytochrome P450 inhibition was 
adapted from BDbiosciences. (San Jose, California, USA). It was used in 
order to determine the IC50 value of the specific CYP inhibitors and the test 
drug propafenone. 
The Cytochrome P450 activity was determined using probe substrates for the 
different bactosomes as shown in Table 2.1. Bactosomes were used as they 
contain the one individual CYP rather than microsomes which contain several 
in different concentrations. The method was based on the principle that the 
metabolism of the probe substrate produces a fluorescent product. 
Fluorescence was measured using a Geniospro Tecan plate reader, with 
excitation and emission wavelength optimised for each substrate (Table 2.1). 
Each plate was run for 10 minutes and a reading of the fluorescence was 
taken at 1 minute intervals. 
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Table 2.1 The specific settings, substrates and inhibitors used for each CYP 
 CYP3A4 CYP2C19 CYP2D6 CYP1A2 
Inhibitor and 
concentration 
used 
Ketoconazole: 
5 µM 
Tranylcypromin
e (TCP): 5 mM 
Quinidine 
25 µM 
Furafylline 
5mM 
Substrate and 
concentration 
used  
7-Benzyloxy-4-
(trifluoromethyl) 
couamrin (BFC) 
 
10 mM 
3-Cyano-7-
ethoxycoumarin 
(CEC) 
 
25 µM 
3-[2-(N,N-DiethylN-
methylammonium) 
ethyl]-7-methoxy-4-
methylcoumarin 
(AMMC) 
10 mM 
 3-Cyano-7-
ethoxycoumari
n (CEC) 
 
25 µM 
Excitation 
wavelength 
(nM) 
410 409 390 410 
Emission 
wavelength 
(nM) 
535 460 465 465 
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Table 2.2 Conditions implemented when using the Genios Pro plate reader 
for the incubations of each bactosome preparation indicating the temperature 
range, wavelength the test is read at (shown for CYP1A2 here), the 
measurement mode and the part of the plate to be read. 
The settings for the Genios Pro plate reader for each incubation are shown in 
Table 2.2. The example here is for CYP1A2, all other experiments had the 
same settings except for the excitation and emission wavelengths shown in 
Table 2.1 
 
2.4.1 Measurement of Cytochrome P450 activity 
 A volume of 100 µL of the appropriate cofactor mixture was added to 3 wells 
of the 96 well plate, to which 100 µL of enzyme substrate mixture was added 
to the 96 well plate. The final volume was therefore 200 µL. Fluorescence was 
Measurement mode:   Fluorescence Top 
Excitation wavelength: 410 nm 
Emission wavelength: 465 nm 
Gain (Manual): 40  
Number of flashes: 10  
Lag time: 0 µs 
Integration time: 40 µs 
Part of the plate: A1 - C12 
 
 
Number of kinetic cycles: 30  
Kinetic interval: 60 s 
Valid temperature range: 36 - 38 °C 
Target Temperature: 37 °C 
Current Temperature: 37 °C 
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measured at wavelengths specified in Table 2.1. The experiment was 
conducted over 10 minutes at 37ºC and values were recorded at 1 minute 
intervals using the Tecan Genios Pro plate reader. 
For the different experiments the final CYP concentrations were as follows; 
CYP3A4 - 4.4pmoles/ µL, CYP2C19 - 4.7 pmoles/ µL, CYP2D6 - 3.0 pmoles/ 
µL and CYP 1A2 - 6.0 pmoles/ µL. 
2.5 Inhibition of CYP Activity by Standard inhibitors and Propafenone  
Incubation conducted the same as in 2.4 but with the addition of a specific 
inhibitor (see Fig 2.1) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A x x x x x x x x x x O O 
B x x x x x x x x x x O O 
C x x x x x x x x x x O O 
D x x x x x x x x x x O  O 
E x x x x x x x x x x O O 
F x x x x x x x x x x O O 
G             
H             
Figure 2.1. Diagram of 96 well plate indicating the contents and relative 
concentrations of each incubation. 
 3 replications are performed for each assay 
 The shaded area represents the presence of inhibitor. The decrease in 
shading represents the dilution of the inhibitor 
 X symbolises the wells that contain CYP and Substrate 
 O symbolises the presence of the substrate.  
Well 11 contains the maximum concentration of inhibitor and the 
substrate. Well 12 contains only the substrate 
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The incubation mixture contained the individual bactosome at the CYP 
concentrations specified in section 2.4. The specific inhibitor for each 
bactosome, the fluorescent probe substrate used at concentrations as stated 
in Table 2.1 and the appropriate cofactor mixture (2.2). 
The final volume was 200µL with the maximum well concentrations of the 
inhibitors furafylline,100 µM, TCP, 200 µM, quinidine, 0.5 µM, ketoconazole, 5 
µM and propafenone at 200 µM. 
The inhibitors were diluted threefold between each well. After the serial 
dilutions and prior to the addition of the enzyme- substrate mixture the plate 
was preheated for 10 minutes in the Genios Pro Tecan plate reader at 37ºC.  
2.5.1 Enzyme – Substrate mixture for CYP 3A4 
The enzyme-substrate mixture for CYP 3A4 contained a volume of 8.0 mL 
200 mM phosphate buffer (2.1.1) and 80 µL of BFC (10 mM). 100 µL of this 
mixture was pipetted into wells 11 and 12. To the remaining substrate mixture 
15.5 µL of CYP 3A4 was added. 100 µL of this was pipetted into wells 1 – 10. 
2.5.2 Enzyme – Substrate mixture for CYP 2C19 
The enzyme-substrate mixture for CYP 2C19 contained a volume of 8.0 mL 
50 mM phosphate buffer (2.1.1) and 20 µL of CEC (25 µM). 100 µL of this 
mixture was pipetted into wells 11 and 12. To the remaining substrate mixture 
21.7 µL of CYP 2C19 was added. 100 µL of this was pipetted into wells 1 – 
10. 
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2.5.3 Enzyme – Substrate mixture for CYP 1A2 
The enzyme-substrate mixture for CYP 1A2 contained  a volume of 1.6 mL 50 
mM phosphate buffer (2.1.1), 6.4 mL deionised water and 40 µL of  CEC (25 
µM). 100 µL of this mixture was pipetted into wells 11 and 12. To the 
remaining Substrate mixture 2.4 µL of CYP1A2 was added and then 100 µL of 
this was pipetted into wells 1 – 10. 
2.5.4 Enzyme – Substrate mixture for CYP 2D6 
The enzyme-substrate mixture for CYP 2D6 contained  a volume of 6.97 mL 
50 mM phosphate buffer (2.1.1) and 2.1 µL of  AMMC (10 mM). 100 µL of this 
mixture was pipetted into wells 11 and 12. To the remaining Substrate mixture 
24.5 µL of CYP 2D6 was added and then 100 µL of this was pipetted into 
wells 1 – 10. 
Well 11 contained the maximum concentration of the specific inhibitor and 
substrate. Well 12 contained the substrate. This process was replicated 3 
times for each incubation. Wells 9 and 10 contained only the specific CYP its 
substrate and cofactor. Fluorescence produced in these wells was indicative 
of maximum metabolism of the fluorescent substrate in the absence of an 
inhibitor. 
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2.6 In Vitro Metabolism of Propafenone and its Enantiomers using 
Human Liver Microsomes 
2.6.1 Conditions for HPLC analysis of propafenone. 
Reversed phase HPLC analysis of samples containing propafenone was 
conducted under the following conditions. Isocratic HPLC was conducted 
using an ODS Hypersil 4.6 mm x 250 mm column with a mobile phase 
consisting of water, acetonitrile and methanol in the following proportion 
(25:30:45 respectively), plus 0.03% v/v of triethylamine and 0.05% v/v 
phosphoric acid. The mobile phase was pumped at a rate of 1 mL/ min and 
the eluent was measured at a wavelength of 210 nM. The injection volume 
was 20 µL.  
 
2.6.2 Generation of standard curve for propafenone and its enantiomers 
The concentration of propranolol was constant at 0.5mM and the 
concentration of propafenone varied to produce a standard curve and allow 
quantification of propafenone. The concentrations of propafenone used were 
0.5 mM, 0.2 mM, 0.1 mM, 50 µM, 20 µM. 
2.6.2.1 Stock solution of propafenone (racemate and its enantiomers).  
A stock solution of 5 mM propafenone in a volume of 10mL was made by 
dissolving 18.9 mg of propafenone in deionised water. A second stock of 1mM 
propafenone was made from the above solution. A 5 mM stock solution of the 
internal standard propranolol was made in a volume of 10mL by dissolving 
14.8 mg in water. 
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2.6.3 Method for the determination of the percentage metabolism of 
propafenone and its enantiomers 
1 mM propafenone( final concentration 0.05mM) ( Anzenbacherova et al, 
2003) stock (25 µL) was preincubated for 5 minutes at 37º C with 6 µL of 
human liver microsomes (40 mg/ mL) in 369 µL 0.1 M phosphate buffer (pH 
7.4) (2.1.1) 
A volume of 100 µL 1 mM NADPH was then added to the incubation mixture, 
giving a final volume was 500 µL. 
The control incubations did not contain NADPH; the mixtures were incubated 
for 30 minutes at 37ºC. 
To terminate the reaction 500 µL of acetonitrile was added together with the 
internal standard propranolol (10 µL of 5 mM). The incubation mixtures were 
centrifuged at 13,000 rpm for 10 minutes. 
A 10 µL aliquot of the supernatant was taken and added to 90 µL of the 
mobile phase making a final volume of 100 µL. This was done as it produced 
good separation of peaks. 
This solution was then analysed using HPLC as detailed in section 2.6.1. 
 
2.7 Protein Binding Study 
2.7.1 HPLC analysis 
Isocratic HPLC analysis was conducted using a chiral human serum albumin 
(HSA) column (50 X 3.0mm) purchased from Chromtech (Apple valley, MN). 
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Under the following conditions: flow rate: 0.5 mL/min, detection: UV 210 nM. 
Mobile phase consisted of 5% propan-2-ol in 20mM potassium phosphate pH 
7.0. 
2.7.2 Preparation of working solutions 
1 mM stock solutions were made up for the following propafenone, 
carbamazepine, verapamil, diltazem, desipramine, propanolol, nortriptyline 
and ketoconazole. From these solutions 0.01 mM working solutions were 
made. 
20µL of 0.01mM test solutions (2.7.2) was injected into the HPLC. This was 
repeated 3 times. 
 
2.8 Statistical analysis 
The student T test was used to compare data in this study. With P < 0.05 
taken as a significant difference between the two groups of data. 
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3.0 Results 
3.1 NADPH production by the regeneration system 
The initial aim was to determine the validity of the regeneration system.  A 
NADPH standard curve was produce to allow quantification of the NADPH 
being produced (Fig 3.1). Using the regeneration system for CYP 3A4, 
CYP1A2 and CYP 2C19 the rate of production of NADPH was at its greatest 
for the first 60 seconds of incubation and that the production begins to plateau 
by 5 minutes (Fig 3.2). It is evident that the regenerating system does produce 
NADPH. 
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Figure 3.1 NADPH standard curve measured at 340 nm (n=1) 
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Figure 3.2 Production of NADPH over a period of 5 minutes (n=1) Production 
of NADPH using the NADPH regenerating system.  
 
3.2 Measurement of CYP Activity 
Figures 3.3 to 3.6 show typical graphs for the metabolism of the fluorescent 
substrate in the presence of the respective CYP. This was determined prior to 
any further investigation. Metabolism occurs in a linear fashion over the time 
course measured for all of the CYPs. 
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Figure 3.3. The metabolism of BFC to a fluorescent product by CYP 3A4 
containing bactosomes (n =1) 
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Figure 3.4 The metabolism of CEC to a fluorescent product by 2C19 
containing bactosomes (n=1). 
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Figure 3.5 The metabolism of CEC to a fluorescent product by CYP1A2 
containing bactosomes (n=1).  
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Figure 3.6 The metabolism of AMMC to a fluorescent product by CYP2D6 
containing bactosomes (n=1).  
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3.3 Inhibition Studies using CYP3A4 
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Figure 3.7 The effect of ketoconazole on the metabolism of BFC by CYP3A4. 
Concentrations (µM) of ketoconazole are shown on the graph, values are 
mean of 4 measurements  
 
Figure 3.7 shows the metabolism of BFC to a fluorescent product by CYP3A4 
is decreased by the co-incubation with ketoconazole (CYP3A4 inhibitor) in a 
dose dependent manner. Similarly the metabolism is decreased when co-
incubated with racaemic propafenone (Fig 3.8) and its separate enantiomers 
(Fig 3.9 and 3.10) 
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Figure 3.8. The effect of racaemic propafenone on the metabolism of BFC by 
CYP3A4. Concentrations (µM) of racaemic propafenone are shown on the 
graph values are mean of 4 measurements 
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Figure 3.9 The effect of (R)-propafenone on the metabolism of BFC by 
CYP3A4. Concentrations (µM) of (R)-propafenone are shown on the graph, 
values are mean of 4 measurements 
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Figure 3.10 The effect of (S)-propafenone on the metabolism of BFC by 
CYP3A4. Concentrations (µM) of (S)-propafenone are shown on the graph, 
values are mean of 4 measurements 
 
Figure 3.8 illustrates the inhibition of CYP3A4 with racaemic propafenone. As 
the concentration of inhibitor increases, the rate of metabolism (fluorescence) 
decreases. This effect if more predominant at the higher concentrations of 
racaemic propafenone, for example 22.22µM to 200µM. 
Figure 3.9 shows CYP activity when inhibited by (R)-propafenone. The activity 
is only shown up to 8 minutes despite the incubation continuing for a further 2 
minutes as there was a lack of consistency with measurements after the 8 
minute period. 
Figure 3.10 shows the metabolism of BFC when inhibited by (S)-propafenone. 
Over a period of 10 minutes it follows a similar trend to (R)-propafenone. 
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Figure 3.11 The percentage activity of CYP3A4 when incubated with 
ketoconazole, racaemic propafenone and its enantiomers, values are mean of 
4 measurements ± S.E. 
 
Figure 3.11 compares the percentage activity of CYP3A4 when incubated by 
racaemic propafenone and its enantiomers. This figure illustrates the similarity 
in the effect of both enantiomers which is evident from the calculated IC50 
values (Table 3.1). The percentage activity of CYP3A4 remains higher at 
lower (R)-propafenone concentration in comparison to its opposite 
enantiomer. 
The racemate follows a similar trend but the IC50 is significantly higher than 
(R)- propafenone (P<0.005) (Table 3.1). The figure shows a difference 
between propafenone and CYP3A4’s known inhibitor ketoconazole. 
 58 
Ketoconazole inhibits CYP3A4 to a greater extent its IC50 value is significantly 
lower (P<0.005). 
 
3.4 Inhibition studies using CYP2C19. 
Figure 3.12 shows the metabolism of CEC to a fluorescent product by 
CYP2C19 is decreased by co-incubation with TCP (CYP2C19 inhibitor) in a 
dose dependent manner. Similarly the metabolism is decreased when co-
incubated with racaemic propafenone (Fig 3.13) and its separate enantiomers 
(Fig 3.14 and 3.15) 
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Figure 3.12 The effect of TCP on the metabolism of CEC by 2C19.  
Concentrations (µM) of TCP are shown on the graph, values are mean of 4 
measurements 
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Figure 3.13 The effect of racaemic propafenone on the metabolism of CEC by 
2C19. Concentrations (µM) of propafenone are shown on the graph, values 
are mean of 4 measurements 
 
Figure 3.12 shows that at the highest inhibitor concentration 200µM there is 
complete inhibition of metabolism as seen by no distinct change in 
fluorescence over time.  This was also evident with racaemic propafenone 
with less inhibition occurring at the lower concentrations (Fig 3.13).  
From figures 3.14 and 3.15 it can be seen that the degree of inhibition by the 
two enantiomers is similar which is evident in their IC50 values (Table 3.1). 
 
 60 
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
0 100 200 300 400 500 600
Time (secs)
F
lu
o
re
s
c
e
n
c
e
 (
e
m
is
s
io
n
)
200
66.67
22.22
7.41
2.47
0.82
0.27
0
 
Figure 3.14 The effect of (R)-propafenone on the metabolism of CEC by 
2C19. Concentrations (µM) of (R)-propafenone are shown in the graph, 
values are mean of 4 measurements 
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Figure 3.15 The effect of (S)-propafenone on the metabolism of CEC by 
2C19. Concentrations (µM) of (S)-propafenone are shown in the graph, values 
are mean of 4 measurements. 
 
The percentage activity of CYP2C19 follows a similar trend when incubated 
with TCP, racaemic and (R)-propafenone, however there is a significant 
difference between the calculated IC50  for racaemic propafenone and (R)-
propafenone (P<0.05, Table 2.1). There are no significant differences 
between the activity of the known inhibitor TCP and propafenone and its 
enantiomers. In all instances, inhibition was only evident at concentrations 
greater than 10 µM. (Fig 3.16) 
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Figure 3.16 The percentage activity of CYP2C19 when incubated with TCP, 
racaemic propafenone and its enantiomers. Values are mean of 4 
measurements ± S.E. 
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3.5 Inhibition studies using CYP1A2  
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Figure 3.17 The effect of furafylline on the metabolism of CEC by CYP1A2. 
Concentrations (µM) of furafylline are shown in the graph. Values are mean of 
4 measurements 
 
Figure 3.17 shows that the metabolism of CEC to a fluorescent product by 
CYP1A2 is decreased by co-incubation with furafylline (CYP1A2 inhibitor) in a 
dose-dependent manner. Similarly, the metabolism of CEC is decreased in a 
dose dependent manner when co-incubated with racaemic propafenone (Fig 
3.18) and its separate enantiomers (Fig 3.19 and 3.20) 
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Figure 3.18 The effect of racaemic propafenone on the metabolism of CEC by 
CYP1A2. Concentrations (µM) of racaemic propafenone are shown in the 
graph. Values are mean of 4 measurements 
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Figure 3.19 The effect of (R)-propafenone on the metabolism of CEC by 
CYP1A2. Concentrations (µM) of (R)-propafenone are shown in the graph. 
Values are mean of 4 measurements 
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Figure 3.20 The effect of (S)-propafenone on the metabolism of CEC by 
CYP1A2. Concentrations (µM) of (S)-propafenone are shown in the graph. 
Values are mean of 4 measurements 
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Figure 3.21 The percentage activity of CYP1A2 when incubated with 
furafylline, racaemic propafenone and its enantiomers. Values are mean of 
(n=4) measurements ± S.E. 
 
There is no significant difference in the IC50 values of propafenone and its 
enantiomers which are within 10 µM of each other However, there is a 
significant difference between the inhibitory effects of furafylline and 
propafenone and its enantiomers (P<0.005; Table 3.1). 
 
3.6 Inhibition studies using CYP2D6 
The incubations with CYP2D6 showed the most variability in results of all of 
the CYPs used and consequently the results for racaemic propafenone are 
not shown as they were too inconsistent.  
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Figure 3.22 The effect of quinidine on the metabolism of AMMC by CYPD6. 
Concentrations of quinidine are shown in the graph (n=4). 
 
When CYP2D6 was incubated with quinidine (CYP2D6 inhibitor) the rate of 
metabolism was decreased with increasing concentration of quinidine. Figure 
3.22 shows that at concentrations higher than 0.02µM quinidine inhibition is 
complete with no activity observed. 
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 Figure 3.23 The effect of (R)-Propafenone on the metabolism of AMMC by 
CYP2D6. Concentrations (µM) of (R)-Propafenone are shown in the graph. 
Values are mean of 4 measurements 
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Figure 3.24 The effect of (S)-propafenone on the metabolism of AMMC by 
CYP2D6. Concentrations (µM) of (S)-propafenone are shown in the graph. 
Values are mean of 4 measurements 
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Figures 3.23 to 3.24 show the metabolism of AMMC in the presence of (R) 
and (S)-propafenone. Figure 3.23 shows that at the highest inhibitor 
concentration 200µM there is complete inhibition of metabolism as seen by no 
distinct change in fluorescence over time. This was also evident with (S)-
propafenone with complete inhibition occurring at the highest concentration 
(Fig 3.24). 
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Figure 3.25 The percentage activity of CYP2D6 when incubated with 
quinidine, racaemic Propafenone and its enantiomers. Values are mean of 4 
measurements ± S.E. 
 
Quinidine is a more effective inhibitor of CYP2D6 than the propafenone 
enantiomers (Fig 3.25). It was not possible to conduct statistical tests on this 
data, however the (R)-enantiomer showed greater inhibition than the (S)-
enantiomer (Table 3.1).  
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3.7 IC50 Values 
Table 3.1 The mean IC50 values for propafenone, its individual enantiomers 
and the CYP known inhibitors. Values are expressed as mean ± standard 
deviation (n=4). 
 IC50 (µM) 
Bactosomes Known inhibitor ppf racemate 
10 mM 
(R) ppf enantiomer 
10mM 
(S) ppf enantiomer 
10mM 
CYP 1A2 furafylline (F)  
(5mM) 
8.44 ± 0.44☼ 
121.60 ± 3.86 122.46 ± 6.85 127.02 ± 10.71 
CYP 3A4 ketoconazole (K) 
(0.25mM) 
0.19 ± 0.18*×⌂ 
28.57 ± 3.61× 12.49 ± 1.70 17.74 ± 10.42 
CYP 2D6 quinidine (Q)  
(25uM) 
0.04 ± 0.002 
Not Measured 0.33 ± 0.1 0.57 ± 0.14 
CYP 2C19 TCP  
(10mM) 
60.84 ± 24.75 
59.54 ± 2.72† 42.78 ± 10.41 76.23 ± 35.50 
*P<0.05. IC50 values are significantly different from racaemic ppf and its enantiomers. 
† P<0.05. IC50 values are significantly different from (R) ppf. 
☼P< 0.005. IC50 values are significantly different from racaemic ppf and its enantiomers. 
× P< 0.005. IC50 values are significantly different from (R) ppf 
⌂P< 0.005. IC50 values are significantly different from racaemic ppf 
 
In summary, the data in Table 3.1 indicates that the IC50 value for racaemic 
propafenone was significantly different to (R)-propafenone when incubated 
with CYP3A4 and CYP2C19. The IC50 values for the known inhibitors of 
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CYP1A2 and CYP3A4 were significantly different from propafenone and its 
enantiomers.  
The CYP2C19 assays show a significant difference in IC50 values of racaemic 
propafenone and (R)-propafenone yet when comparing (R)-propafenone and 
the racemate to (S)-propafenone they are statistically similar. 
 
3.8 In Vitro Metabolism of Propafenone and its Enantiomers with Human 
Liver microsomes 
Figures 3.26 and 3.27 are examples of the chromatographs produced 
following HPLC analysis of samples from the incubations conducted to 
measure metabolism. In these examples incubations containing the (S)-
enantiomer are shown. The control (Fig 3.26) shows a large first peak at 4.9 
minutes which is the internal standard propranolol and a smaller second peak 
at 5.6 minutes which is (S)-propafenone. Figure 3.27 shows the results from 
test incubation where the cofactor NADPH was added. There is a large first 
peak at 5 minutes which is the internal standard and the second peak at 5.6 
minutes which has a smaller peak area than the corresponding one in figure 
3.26.  
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Figure 3.26 Typical HPLC trace for (S)-propafenone (peak at 5.6 minutes) in 
control incubations (-NADPH) along with the internal standard propranolol 
(peak at 4.9 minutes). 
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Figure 3.27 Typical HPLC trace for (S)-propafenone (peak at 5.6 minutes) in a 
test incubation (+ NADPH) along with internal standard propranolol (peak at 
4.9 minutes). 
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Figures 3.28 to 3.30 show the peak area ratios for propafenone and the 
internal standard propranolol at varying propafenone concentrations which 
produce standard curves allowing quantification of metabolism. 
y = 2.6714x - 0.0861
R
2
 = 0.9286
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0 0.05 0.1 0.15 0.2 0.25
Concentration Racaemic Propafenone (mM)
P
e
a
k
 A
re
a
/R
a
ti
o
 P
P
F
/P
R
O
P
 
Figure 3.28 Standard curve for racaemic propafenone when incubated with 
the internal standard propranolol (n=1). 
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Figure 3.29 Standard curve for the (R)-enantiomer when incubated with the 
internal standard propranolol (n=1). 
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Figure 3.30 Standard curve for the (S)-Enantiomer when incubated with the 
internal standard propranolol (n=1) 
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Table 3.2 shows that NADPH dependent metabolism by human liver 
microsomes occurred for both racaemic propafenone and its individual 
enantiomers. However, the extent of metabolism was significantly less 
(p<0.001) for racaemic propafenone than for either of the individual 
enantiomers. There was no significant difference in the extent of metabolism 
of the individual enantiomers. 
Table 3.2 Percentage metabolism of racaemic propafenone and its 
enantiomers. Mean ± standard deviation (n=4) 
 Racaemic ppf (R)-ppf (S)-ppf 
% metabolism 16.0 ± 2.3 * 23.7 ± 8.2 27.3 ± 7.2 
* P< 0.001, percentage metabolism is significantly lower compared to the 
enantiomers 
 
3.9 Protein Binding 
The results for protein binding for the standard drugs used are shown in 
Figure 3.31. Protein binding levels are similar, although there is a consistent 
overestimate for protein binding when compared with that found in the 
literature (www.chromtech.se). There was no difference in protein binding for 
the two separate enantiomers of propafenone when determined in this 
manner. When the racaemic form of propafenone was used both, 
enantiomers co-eluted from the column. The amount of protein binding 
 76 
calculated by this method was 88.6%.  Typical HPLC traces for propafenone 
and also for propranolol are shown in figures 3.32 and 3.33.  
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Figure 3.31 Comparison of published data (chromtech. com) to data compiled 
in this study. The percentage protein binding of different compounds is 
represented the graph shows the compounds in the following order; 
carbamazepine, ditiazem, desipramine, propranolol, verapamil and 
propafenone. 
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Time (minutes) 
Figure 3.32 Chromatograph of 0.01 M propafenone on the HSA column and 
its retention time of 4.16 minutes. 
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Time (minutes) 
Figure 3.33 Chromatograph of 0.01 M propranolol on the HSA column 
showing its retention time of 3.49 minutes. 
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4.0 Discussion 
4.1 Background 
The aim of this study was to assess the differences in the disposition and 
metabolism of propafenone enantiomers in particular with regard to the 
interaction with the major human forms of cytochrome P450. This was 
primarily done through analysis of racaemic propafenone and its individual 
enantiomers’ inhibitory effects and their metabolism by cytochrome p450. 
As previously described, propafenone is a class IC antiarrhythmic drug and its 
therapeutic use is flexible as it can be used for both short and long term 
treatment of arrhythmias. It can e administered both orally and intravenously. 
Each course has its benefits, for example; intravenous administration is 
effective for ventricular arrhythmias whereas an oral dose is an effective form 
of management of chronic re-current supraventricular tachycardia 
(www.patft.uspto.gov ). Propafenone is a chiral compound and It has been 
established that both enantiomers exert similar sodium channel blocking 
abilities, but further research has shown that it is the (S)- enantiomer that 
produces greater beta adrenoreceptor blocking capabilities which is important 
as beta blockers are the only cardiovascular drugs clearly effective in 
preventing sudden cardiac death in patients with prior heart attacks (Kroemer 
et al, 1994).  As propafenone is normally administered as a racemate it is 
important to investigate the efficacy of the drug to determine if it is more 
efficient to administer one enantiomer as opposed to the racemate. This study 
focuses on the metabolism and distribution of the enantiomers and if there are 
any stereospecific differences which affect the therapeutic efficacy of 
propafenone. The aim of the study was to look at each enantiomer 
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individually. Acquiring samples of the individual enantiomers was difficult; it 
was time consuming and so during the interim period other means to separate 
the racemate drug were explored. For example using a chiral column (Zhong 
and Chen, 1999), A reverse phase ODS column (Yong-Jiang and Ming-Ming, 
2004), or using diastereomeric salt formation (Kroemer et al, 1994). Whilst 
these methods were viable options the availability of individual enantiomers 
from Knoll AG allowed the study to progress without having to resort to their 
use.  
 
4.2 Inhibition studies. 
The inhibition studies measured the interactions between propafenone, its 
enantiomers and the human CYP isozymes CYP1A2, CYP 2C19, CYP 2D6 
and CYP3A4. These studies were based on a method using a fluorescent 
probe substrate. The individual CYP metabolises the probe substrate to its 
fluorescent product which can be measured to determine enzyme activity. For 
example, for the incubations of CYP3A4, the substrate BFC is metabolised to 
its fluorescent product HFC. To allow higher throughput, the method was 
scaled down to be conducted in a 96 well plate and fluorescence was 
measured using a plate reader. Automated assays using this type of 
technology have proved to be an advantage as they relieve human burden 
and reduce error involved with manual operations (Yao et al, 2007). Inhibition 
occurs following the co-incubation of the different CYP substrates with 
another compound (in this instance the standard CYP inhibitor and 
propafenone) resulting in a decrease in fluorescence. The degree of inhibition 
was quantified by determining the IC50 (i.e. amount of drug causing 50% 
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inhibition of enzyme activity) which can be related to the drug’s affinity for the 
enzyme (Barile, 2004). This high throughput screening method is used 
regularly by the pharmaceutical industry to estimate the involvement of single 
or multiple enzymes involved in drug metabolism and to screen the inhibitory 
potency of drugs under development through calculation of their IC50 values 
(Yamamoto et al, 2003; Turpeinen et al, 2006). 
The actual method developed for this study was adapted from one described 
by BD Biosciences which utilised a NADPH regenerating system. This system 
was chosen rather than a single addition of NADPH to ensure a constant 
supply of co-factor to maintain the reaction for the duration of the incubation. It 
was found that the NADPH regenerating system was effective in generating 
and maintaining NADPH levels throughout the reaction time (Fig 3.2). The 
results for the metabolism of the test substrates by the different CYP isoforms 
show that there was a constant rate of metabolism as seen by a linear 
production of metabolite (fluorescence) with time. The presence of an inhibitor 
was found to decrease the reaction rate in a dose dependent manner as 
observed by a decrease in fluorescence. This allowed the production of 
inhibition curves which were used to calculate IC50 values for standard 
inhibitors and propafenone (Table 3.1). Whilst the results for CYP1A2, CYP 
3A4 and CYP2C19 showed a high degree of reproducibility, this was not the 
case with CYP2D6 which, despite numerous attempts it did not display the 
same level of consistency. 
Overall the IC50 values calculated in this study are higher than those found in 
the literature. For example it has been suggested that the IC50 of propafenone 
is 20 µM for the inhibition of CYP1A2 (Zhou et al, 2003) and 0.02 µM when 
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incubated with CYP2D6 (McGinnity et al, 2008). BD Biosciences state the IC50 
values for ketoconazole, quinidine, TCP and furafylline to be 0.05 µM, 0.014 
µM, 0.75 µM and 1.3 µM respectively. The IC50 values calculated in this study 
for the known inhibitors of the individual CYP’s are all consistently higher. This 
result was unexpected and so further investigation would help to determine 
why there is such a difference and the difference in in vitro systems used 
could be factor one worth investigating. Indeed, it has been suggested that 
factors such as non-specific binding resulting from the high protein content of 
incubations used by some laboratories may result in erroneous results in 
these types of studies (Austin et al, 2002).  
  
4.2.1 Inhibition with CYP 3A4. 
The incubations with CYP3A4 show that (R) and (S)-propafenone have similar 
inhibitory properties. The IC50 values for propafenone racemate and 
enantiomers are all significantly greater than those for the standard inhibitor 
ketoconazole. However, both enantiomers show mean IC50 values which are 
lower than for the racemate although only the (R)-enantiomer and the 
racemate are significantly different (p< 0.005) (Table 3.1). 
 These findings indicate that (R)- propafenone is the more potent inhibitor 
showing a stereospecific difference in interaction of propafenone enantiomers 
with CYP3A4. This is important clinically as CYP3A4 is the major human form 
of P450 responsible for the metabolism of a high number of drugs and so 
inhibition of this enzyme has a high potential for drug-drug interactions. 
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4.2.2 Inhibition with CYP2C19. 
Propafenone and its enantiomers had statistically similar IC50 values as 
CYP2C19’s known inhibitor TCP. It was only (R)-propafenone which was 
significantly different from the racemate. In this experiment, greater variability 
was found with the enantiomers of propafenone as opposed to the racemate.  
The IC50 values were relatively high when compared to the standard inhibitor 
(TCP). Therefore, it would be expected that inhibition of CYP2C19 would be 
minor and indeed no evidence has been reported for this type of interaction. 
The IC50 value for (S)-propafenone is higher than that of the (R)-propafenone 
and the racemate; therefore it is indicative of a lower affinity for the enzyme 
than is seen with the (R)-enantiomer and the racemate (Fig 3.16 and Table 
3.1).  
 
4.2.3 Inhibition with CYP1A2. 
Analysis of CYP1A2 showed that there were no significant differences in the 
IC50 values for propafenone and its enantiomers. However, the results do 
show that as an inhibitor of CYP1A2, racaemic propafenone and its 
enantiomers are relatively poor inhibitors of CYP1A2 when compared to 
furafylline (CYP1A2’s known inhibitor) which had an IC50 value of 8.44 µM. 
There are conflicting reports for the IC50 of propafenone on CYP1A2, with 
values ranging from 20 µM to 0.225 mM (Zhou et al, 2003). However, in a 
study on the co-administration of propafenone with caffeine it has been 
reported that propafenone causes significant inhibition of CYP1A2 activity in 
vivo (Michaud et al, 2006). In the case of CYP1A2 there appeared to be less 
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variability than with the other CYPs. There is no significant difference in the 
inhibitory effects of propafenone or its enantiomers on the activity of CYP1A2 
(Fig 3.21) indicating that there are no stereospecific differences in 
propafenone metabolism by CYP1A2. The results do tally with expected 
involvement of the different CYPs i.e. the main metabolic pathways for 
propafenone involve CYP2D6 and CYP3A4 rather than CYP1A2. 
 
 
4.2.4 Inhibition with CYP2D6. 
The assays involving CYP2D6 were more difficult to perform as there was 
considerable variability between the inhibitory effects of propafenone and its 
enantiomers (Fig 3.25 and Table 3.1) which resulted in no IC50 value being 
calculated for the racemate in this instance. In comparison to CYP2D6’s 
known inhibitor quinidine, the IC50 values for the enantiomers was 
approximately greater by a factor of tenfold. The IC50 value calculated in this 
study for quinidine was 0.037 µM which is more than double that stated in the 
literature (BD Biosciences.com). This could be because, when performing the 
assay it proved the most difficult to reproduce. As a result of the problems in 
obtaining data it was not possible to conduct any statistical tests, although the 
(R)-enantiomer exhibited a greater inhibitory effect than the (S)-enantiomer. 
The potential for propafenone and its enantiomers to cause significant drug-
drug interactions is highlighted by the low IC50 values determined in this study. 
Furthermore, individuals displaying a slow metaboliser phenotype for CYP2D6 
would show even greater effects as it is possible that metabolism could be 
inhibited to an even greater extent in this case. The findings for CYP2D6 
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mirror those of CYP3A4 where (R)-propafenone proves to be the more potent 
inhibitor. In comparison to the other bactosomes used in this study, 
propafenone did prove to be the most potent inhibitor when incubated with 
CYP2D6. This is important as previously discussed CYP2D6 is responsible 
for the metabolism of more than 40 drugs, therefore the inhibitory effect of 
propafenone on CYP2D6 could reduce the effectiveness of other drugs when 
co-administered (Hemeryck et al, 2000). Further investigation into refining this 
method could therefore be warranted. 
Overall, the IC50 results (Table 3.1) show that propafenone is the most potent 
inhibitor of CYP2D6 in comparison to the other CYPs tested. The results also 
indicate that propafenone is least effective as an inhibitor when incubated with 
CYP1A2. A major finding from these studies has been that (R)-propafenone 
shows the greatest inhibitor effect for each CYP except CYP1A2.  Further 
studies are required to investigate the in vivo effect of propafenone and its 
enantiomers with regards to CYP interaction and inhibition.  It is apparent that 
the CYP isoforms which have been shown to be the major ones responsible 
for the Phase 1 metabolism of propafenone display the greatest amount of 
inhibition (namely CYP2D6 and CYP3A4).  This is not unexpected as it is with 
these CYP isoforms that the greatest binding affinity/interaction would be 
predicted. Therefore, it may be expected that the (R)-enantiomer would 
undergo more metabolism especially with CYP3A4 and CYP2D6. In fact this 
is not the case, although the individual enantiomers display more metabolism 
than the racemate. This may be due to relative amounts of CYP in the 
microsomal fraction used in the metabolism studies, but it could also suggest 
that the inhibition assays are not always able to predict stereoselective 
 86 
differences. Future investigation could include the repetition of the inhibition 
study using human liver microsomes rather than the individual bactosomes as 
this is what exists in the body naturally. This can be an issue as an increase in 
protein concentration can change the non-specific protein binding. Further 
investigation could determine if there are any similarities between the 
individual CYPs used throughout this study.  
 
4.3 In Vitro Metabolism of Propafenone and its Enantiomers with Human 
Liver microsomes 
The metabolism study was performed using human liver microsomes which, 
unlike the bactosomes used in the inhibition study, contain a mixture of CYP 
isoforms. This, of course, is the situation found in vivo, but it can make the 
data more difficult to analyse. Ideally, the metabolism study was to be carried 
out using  chromatographic separation with mass spectrometer analysis (LC-
MS) to detect the presence of propafenone and metabolites,  but 
unfortunately this was not possible and so the study was performed using  
HPLC with diode array detection. This method yielded accurate results and 
enabled quantification of metabolism by measuring how much parent 
propafenone remained at the end of the incubation. 
Consideration was given to various methodologies to extract the parent drug 
and metabolites from the incubation samples prior to HPLC analysis. These 
included the use of solid phase extraction as has previously been described 
for the phase 1 metabolites 5-hydroxypropafenone and N-
despropylpropafenone (Hoffman et al, 2000). Another option was the use of 
dichloromethane as an agent to carry out the extraction and concentration of 
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the samples (Pires de Abreu et al, 1999). Ultimately the method used in this 
study (refer to section 2.6.5) was chosen due to its simplicity, speed and not 
having to carry out extensive sample preparation. 
Whilst the use of HPLC methodology is an extremely powerful one for the 
separation and quantification of drugs and their metabolites, it was not without 
its problems. The technique was not always reliable with equipment failure 
being the greatest problem which limited the number of studies to be 
conducted. In developing the method, the original mobile phase chosen 
contained water, acetonitrile and methanol at the following proportions 
(56:16:28 v/v/v). This mixture also contained 0.03% triethylamine and 0.05% 
phosphoric acid and was based on a method described by Zhou et al (2001). 
The concentrations of the individual components were altered as the retention 
time was significantly longer then anticipated. The organic element of the 
mixture was increased because the column is lipophillic therefore increasing 
the lipophillic part of the solvent meant that the compounds were eluted 
quicker. The final mobile phase contained water, acetonitrile and methanol 
(25:30:45 v/v/v). This alteration now ensured that the propafenone and 
internal standard propranolol peaks were produced at around 6-7 minutes 
whilst still retaining the separation of propafenone from the internal standard 
and metabolites. 
 
 4.3.1 Percentage metabolism 
From the chromatographs (Fig 3.26 and 3.27) it is clear that adequate 
separation was achieved to allow quantification of propafenone levels.  The 
results are interesting in that the percentage metabolism of the racemate was 
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considerably lower than that of the enantiomers. It has been reported that, 
when incubated together, (R)-propafenone will inhibit the metabolism of (S)-
propafenone (Zhou et al, 2003).  This may explain the decreased metabolism 
observed with the racemate as opposed to the individual isomers. When 
comparing the metabolism of the individual enantiomers the difference is not 
significant, although the (S)-enantiomer experiences more metabolism than its 
counterpart which is in agreement with previous work (Zhou et al, 2003). As 
mentioned earlier in this discussion, the results of the inhibition studies may 
suggest that the (R)-enantiomer would experience more metabolism as it had 
a greater affinity to CYP3A4 and CYP2D6 in comparison to the racemate and 
(S)-propafenone which is not the case.  It would have been fascinating to 
confirm which CYP specifically was involved in the metabolism of 
propafenone by HLM as this would also allow a better comparison between 
the inhibition studies. This could be achieved by using specific CYP inhibitors 
in incubations with HLM. This is a point for future research in this area. 
 Bringing together the results of all of the studies, they show that overall the 
(S)-enantiomer had the greatest percentage metabolism in comparison to the 
racemate and the (R)-propafenone which was unexpected as the (S)-
propafenone showed a lower affinity to all of the CYPs used in the inhibition 
study compared to the (R)-enantiomer and the racemate in particular with 
CYP2C19 and CYP1A2. Yet the inhibition study proved that it was not 
significantly different to the racemate in its inhibitory effects. Although there 
were differences in the activity of the CYPs used in the study, the metabolism 
study has shown that the individual enantiomers are metabolised to a greater 
extent than the racemate which could be problematic when using only one 
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enantiomer for therapy rather than the racemate. The half life for propafenone 
is short which necessitates regular dosing. Decreasing the half life even 
further could be unacceptable for the use of the drug in vivo. This is in 
contrast to the inhibition study which suggests administering the (S)-
enantiomer would be the best option as (R)-propafenone shows the greatest 
inhibitory effect and is metabolised and cleared at a greater rate than its 
opposite enantiomer. Therefore, further study both in vitro and in vivo is 
warranted to investigate the feasibility of enantioselective therapy of 
propafenone. 
 
4.4 Protein Binding 
Protein binding is an important factor as many critical pharmacokinetic 
parameters such as metabolism rate, renal excretion rate and steady-state 
distribution volume are the effect of the unbound drug fraction (Cheng et al, 
2004). Therefore, the higher affinity a drug has for the protein the slower the 
disassociation rate will be, creating lower clearance rate and increasing the 
elimination half life (Sear 2007). HSA was used as it is the most abundant 
protein found in human blood and plasma (Cheng et al, 2004). It has two 
major binding sites known as the warfarin-azapropazone and the indole-
benzodiazepine site. The methods primarily utilised to determine drug-protein 
binding are equilibrium dialysis (Kwon, 2001) and ultrafiltration (Crommelin et 
al, 2002). There are advantages and disadvantages to both of these methods. 
For example equilibrium dialysis is temperature controlled and known as the 
standard procedure yet it takes a long time to reach equilibrium. Ultrafiltration 
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is a fast process and requires a small amount of sample but the volume of 
ultrafiltrate may not be suitable for drugs assays (Kwon, 2001).  
This study employs a novel and faster method of analysis. The sample 
preparation was simple and so experimental duration was significantly 
shorter. 
The protein binding study showed the difference in distribution of propafenone 
compared to other compounds. The HSA column is chiral and is able to 
separate racaemic compounds directly. The results show that the racaemic 
propafenone did not separate and therefore the enantiomers eluted at the 
same time as the racemate. This means that both enantiomers exhibit similar 
protein binding to the racemate on HSA and that there is no stereospecific 
variation in the binding of the different enantiomers. Therefore there is no 
influence on disposition in vivo and so the enantiomers have the same 
amount of unbound drug free to undergo biological processes such as 
metabolism and elimination. This data is in agreement with that published by 
Hong et al (2009) who also found that binding to HSA was not 
enantioselective. In addition figure 3.21 shows propafenone has one of the 
highest percentage protein binding of 88.6% second only to desipramine at 
91.2% in this experiment. This study is in agreement with published data 
indicating that propafenone exhibits a high protein binding of 95% (Ijaz and 
Khan, 2001). However, propafenone has also been shown to bind to alpha 1 
acid glycoprotein in an enatioselective manner and so further studies in this 
area would need to take this binding into account (Hong et al, 2009). 
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4.5 Scope for Future work 
It is known that CYP2D6 and CYP3A4 are the main CYPs to metabolise 
propafenone. In the future more work should be done to concentrate on 
CYP2C19 as it appears to be understood far less than any of the other CYPs 
in this study. The inhibition studies yielded interesting results in that it proved 
CYP2C19 was inhibited by propafenone to a greater extent than CYP1A2. A 
study of its metabolism properties would be interesting to see. Future studies 
should also include the use of LC-MS to look at the individual metabolites 
being produced and to quantify rate of metabolism. Are certain metabolites 
being produced in greater concentrations than others and which pathway is 
favoured?  
 
4.6 Problems and Developments 
Throughout this study there were several obstacles to overcome for example, 
the inhibition study involving CYP2D6. Concordant results were difficult to 
achieve in comparison to the other CYPs, it took several replications to 
achieve the results (Fig 3.23 and 3.24). When performing this test the well 
containing the blank was consistently high and some instances it was higher 
than the test samples. This observation was unexpected as the blank only 
contained the substrate. The substrate was frozen to allow use over several 
sessions and so this could have affected its efficacy, therefore it was chosen 
to make it up fresh and the results were more consistent. Due to this the 
reliability of the CYP2D6 results are questionable. This test was performed 
under the same conditions in terms of the preparation stages and incubation 
time. The only major difference was the use of different cofactors. The 
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cofactor used for CYP2D6 was eight times more concentrated. With more 
time the incubations could be performed using the other cofactor mix to see if 
there was any change in CYP2D6’s behaviour. Also it would be interesting to 
see the results using the other substrate MAMC. 
The metabolism study used human liver microsomes rather than the individual 
bactosomes. This was done as neither the time or the money was available to 
invest in new sets of bactosomes and so it was chosen to use human liver 
microsomes for the metabolism incubations.  
The original method for the metabolism study (refer to 2.6.3) was developed 
as there was no propafenone peak visible when the samples were analysed. 
There was definitely propafenone in the system and so this was unexpected. 
Therefore after checking the injector and the column by running 10µL of 1mm 
propafenone dissolved in water, a peak was produced. In order to investigate 
this occurrence further the sample was dissolved in the mobile phase. A 10 µL 
aliquot of the sample mixture was added to 190 µL of mobile phase and ran. A 
peak was now visible but the optimum conditions to produce good separation 
and resolution of the peaks needed to be ascertained. It is believed that the 
phosphate buffer was interacting with the sample solution and having a 
negative effect on the sample mixture and causing no peak to be recorded. 
Different ratios of the sample and mobile phase were tested to determine the 
one that produced the best separation and resolution. A 1 in 10, 1 in 20, 1 in 
50 and 1 in 100 were tested and ultimately it was decided that the 1 in 10 
dilution yielded the best results. The flow rate was reduced from 1 ml/minute 
to 0.5 ml/ minute as the peaks were now coming off at around 3 minutes 
which interfered with the solvent front. 6 minutes was the desired run time. 
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The samples were diluted to 1 in 10 with the mobile phase and then run from 
that point onwards; therefore the results obtained in section 3.8 were done so 
using this alteration. This change proved to work well which is visible from the 
chromatographs (Fig 3.26 and 3.27) 
 
In conclusion there are many factors which affect a drugs efficacy. 
Investigating racemate therapy is difficult. Treatment with the individual 
enantiomers or racaemic propafenone have advantages and disadvantages, 
which are indicated in this study. Each CYP analysed in this study is inhibited 
by propafenone to varying degrees but there is room for further investigation 
especially in terms of the inhibition of HLM as that is how it naturally occurs in 
the body. This study has exposed the interactions of propafenone and its 
enantiomers with the major human forms of cytochrome P450, yet it cannot 
conclusively say that therapy using individual enantiomers is the best form of 
treatment in this case. Work in this area needs to be continued. 
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